For years, a prescription for an overactive bladder has come with an unspoken trade: relief from the constant urge to go, at the price of a nagging worry about memory. A Cleveland team has now run that worry against the records of 830,393 patients, and the answer is less alarming than the folklore suggests.
The researchers, at University Hospitals Cleveland Medical Center, report in JAMA Network Open that dementia rates were similar across the two main drug classes and across individual medications. The paper appeared Nov. 6, and the lead author is careful not to oversell it.
Where the dementia worry came from
Anticholinergic drugs block acetylcholine, a brain chemical tied to attention and memory. KFF Health News reported in 2019 that the American Geriatrics Society’s Beers Criteria has listed such drugs as potentially inappropriate for older adults since 2012, and that a JAMA Internal Medicine study of more than 284,000 British adults aged 55 and older linked taking a strong anticholinergic daily for three years to a 49% higher dementia risk. Bladder-control medicines were among those with the most pronounced effects in that work, which showed an association rather than proof of cause.
Overactive bladder pills came under a second line of suspicion from a head-to-head comparison. A 2020 retrospective study by Welk and McArthur in BJU International, discussed in a 2021 editorial in the International Brazilian Journal of Urology, found that anticholinergic users carried a higher dementia risk than users of beta-3 agonists, the newer class that works on the bladder muscle differently. The hazard ratio was 1.23. The editorialist called the effect small but measurable, and noted that prescription records do not show whether patients actually took the drugs.
Findings like these helped make beta-3 agonists the presumed safer-for-the-brain option, a status the new paper puts to the test.
830,393 patients in Epic Cosmos
The Cleveland group drew on Epic Cosmos, a national electronic health record database, according to the University Hospitals release. It followed adults aged 40 to 90 who were newly treated for overactive bladder between 2012 and 2025. The paper, titled “Drug Therapies and Incidence of Dementia Among Adults With Overactive Bladder,” is available under its journal DOI.
A summary by the American Journal of Managed Care, which reviewed the full paper, gives the detail the release leaves out. Patients had a median age of 67 and 70.5% were women. Most started on what the authors classed as high-risk anticholinergics (oxybutynin, tolterodine, solifenacin), 572,489 people. Another 49,592 started on low-risk anticholinergics (darifenacin, trospium, fesoterodine) and 208,312 on beta-3 agonists (mirabegron, vibegron). Dementia developed in 65,134 patients, or 7.8%.
After weighting, the high-risk anticholinergic group had a hazard ratio of 0.90 against beta-3 agonists, with a confidence interval of 0.87 to 0.93, meaning slightly fewer dementia diagnoses rather than more. Low-risk anticholinergics came in at 0.97 (0.93 to 1.01), not a significant difference. Weighted 10-year dementia risk was 20.0% for beta-3 agonist users, 19.0% for low-risk anticholinergics and 18.1% for high-risk anticholinergics, the AJMC report says.
A cautious reading from the lead author
David Sheyn, a urogynecologist at University Hospitals and the study’s lead author, did not tell patients to change course. Instead, he said in the release that “beta-3-agonists are still considered the better choice whenever possible,” and that the results are “still new and will require reproduction prior to a change in clinical guidelines.”
The design has limits that Sheyn and colleagues acknowledge. The study compared drug classes and did not include patients who took no medication, so it cannot show that the pills carry no risk. Dementia events outside the Cosmos network were not captured, exposure was based on prescriptions rather than dispensing, and dose data were often missing. E-values of 1.29 and 1.20 in the AJMC summary mean that modest unmeasured confounding could erase the small gaps seen between groups.
Anticholinergics are also tied to short-term memory and cognitive side effects in some patients, which the authors say resolve after stopping the drug. Memory side effects while on the drug are a separate matter from the question of whether the drugs raise the long-term chance of a dementia diagnosis.
Is the bladder a warning sign?
Sheyn offered an alternative reading of the old signal. Dementia-related processes often begin decades before symptoms appear, he noted, and most earlier studies followed patients for five years or less. The authors suggest that overactive bladder itself, and the neurologic mechanisms behind it, may be an early warning sign of neurodegenerative processes. They stress that the data “cannot prove that OAB is an early sign of dementia on its own” and show only that the pattern fits.
Such a pattern could explain why earlier studies found a link without the drugs being the cause: people already on the road to dementia may be more likely to be prescribed a bladder medicine in the first place. The AJMC summary adds that preferential prescribing of beta-3 agonists to patients judged to carry higher cognitive risk is one possible explanation for the small differences. Whether another large dataset reproduces the Cleveland result is the question that will decide if guidelines ever move.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- A handful of car transmissions are so tough that mechanics say they almost never die
- Melting permafrost is setting off a newly identified kind of catastrophic landslide, scientists say
- Cadillac cut the price of its cheapest EV, which goes up to 317 miles on a charge
- Winter weather advisories cover I-80, I-70 and the Bighorns with up to 15 inches of snow